News for Adagene Inc. (ADAG)

SAN DIEGO and SUZHOU, China, April 07, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (”œAdagene”) ( ADAG), a company transforming the discovery and development of

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEb

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (”œAdagene”) ( ADAG), a company transforming the discovery and development of

**media[559091]**

- Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO

Transaction Overview On December 31, 2024, FIL Ltd (Trades, Portfolio), a renowned asset management firm, strategically increased its stake in Adagene Inc (ADAG

Muzastotug (ADG126), an Anti-CTLA-4 SAFEbody® in Combination with pembrolizumab showed 33% overall response rate in microsatellite stable colorectal cancer Fo

SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (”œAdagene”) ( ADAG), a company transforming the discovery and development of n

Here is how Adagene Inc. Sponsored ADR (ADAG) and Editas Medicine (EDIT) have performed compared to their sector so far this year.

Shares of Adagene Inc. (ADAG) experienced significant volatility, dropping 5.97% to $1.89. The trading volume reached 26,937 shares with a turnover rate of 0.06

Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Adagene reports new findings at SITC meeting

The allogeneic hematopoietic stem cell transplant market is expected to experience significant growth in the coming years, driven by advances in...

Adagene Inc. (ADAG), a clinical-stage biopharmaceutical company, experienced a significant stock movement with a 5.43% surge in its share price. The stock is cu

Shares of Exicure, Inc. XCUR rose sharply in today's pre-market trading after the company entered into debt-for-equity exchange agreements and regained Nasdaq c...

The stem cell market is experiencing positive growth due to several factors, including the increasing prevalence of chronic diseases, the need for drug...

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.

HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously working towards developing 85+ HER2 negative Breast Cancer treatment...